merck_kapa_biosystems

Merck and Roche extend distribution ties

pharmafile | December 5, 2016 | News story | Manufacturing and Production Merck, Roche, distribution 

Merck KGaA and Roche have announced that they will further increase the distribution links between the two companies by having Merck be responsible for distribution of Roche’s polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems. Kapa Biosystems was acquired by Roche in 2015, in a deal that saw Roche increase its presence in next-generation sequencing (NGS) products.

Under the terms of the agreement, Merck will present and distribute Kapa PCR and quantative PCR reagents and kits. The distribution deal covers all geographic channels, except the US, Japan and Brazil. The deal does not extend to NGS products, which will remain the offering of Roche Sequencing Solutions.

Merck and Roche have previous links after Roche had agreed an exclusive distribution agreement of its Biochemical Reagents with Sigma-Aldrich in 2015. Merck then acquired Sigma-Aldrich  in the same year.

The deal is expected to become active by the beginning of the next year.

“This agreement represents a powerful combination of Kapa’s high-quality PCR and qPCR products with the excellent e-commerce and distribution channels of Merck KGaA, Darmstadt, Germany,” said Uwe Oberlander, Head of Roche Molecular Diagnostics. “We believe this partnership will provide improved access to these products for researchers in many countries around the world.”

Ben Hargreaves

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 …

Latest content